Shire wants out of that $172M Bax­al­ta deal with CTI Bio

A few weeks af­ter Seat­tle-based CTI Bio­phar­ma’s $CTIC trou­bled myelofi­bro­sis drug pa­cri­tinib turned in some mixed late-stage da­ta, Shire is prepar­ing to punt its in­ter­est …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER